Mendus AB (publ) (IMMU.ST) Research

Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.

Market snapshot

Symbol
IMMU.ST
Price
$6.30
Day change
+14.55%
Market cap
$319.8M
P/E ratio
-3.32x
52-week range
3.86-10.98
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Ascelia Pharma AB (publ) (ACE.ST)
  • Corline Biomedical AB (CLBIO.ST)
  • Elicera Therapeutics AB (publ) (ELIC.ST)
  • Isofol Medical AB (publ) (ISOFOL.ST)
  • Intervacc AB (publ) (IVACC.ST)
  • Karolinska Development AB (publ) (KDEV.ST)
  • Lipum AB (publ) (LIPUM.ST)
  • Magle Chemoswed Holding AB (publ) (MAGLE.ST)

Open Mendus AB (publ) (IMMU.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.